The FDA and Feasible Alternative Designs
Drug & Device Law
FEBRUARY 20, 2023
151, 163-68 (2001)) (lengthy discussion of FDA regulatory process omitted). In at least the short term, a popular pain reliever would have to be removed from pharmacies. 7, 2022), which addressed the same question in the context of the admissibility of expert testimony. His testimony is thus irrelevant and inadmissible.
59 
Let's personalize your content